A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

The American Academy of Dermatology/National Psoriasis Foundation (AAD/NPF) guidelines state that "topical medications are the most common agents used to treat patients with mild or moderate ...

Company News Published 07/02/2025, 07:49 AM 0 FDA partially lifts clinical hold on VYNE’s VYN202 psoriasis trial VYNE -5.63% ...

Those include having a Psoriasis Area and Severity Index (PASI) of 10 or more – indicating that lesions cover at least 10% of their body – and a Dermatology Life Quality Index (DLQI) score ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...